Darolutamide is a medication used to treat prostate cancer. Specifically, it is a non-steroidal androgen receptor inhibitor, meaning it blocks the action of androgens (male hormones like testosterone) which can promote the growth of prostate cancer cells. Darolutamide is often used in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), which is a type of prostate cancer that continues to grow despite low levels of testosterone in the body. It is marketed under the brand name Nubeqa and is usually administered in combination with other treatments like androgen deprivation therapy (ADT).